Received Apr 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (INFANRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Infanrix administration instead of Boostrix; Infanrix administration out of the recommended age; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong vaccine administered in a 10-year-old male patient who received DTPa (Infanrix) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) (batch number X449Y) for prophylaxis. On 17-MAR-2025, the patient received Infanrix. On an unknown date, the patient did not receive Boostrix. On 17-MAR-2025, an unknown time after receiving Infanrix and not applicable after receiving Boostrix, the patient experienced wrong vaccine administered (Verbatim: Infanrix administration instead of Boostrix) and inappropriate age at vaccine administration (Verbatim: Infanrix administration out of the recommended age). The outcome of the wrong vaccine administered and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 21-APR-2025 Office Manager wanted to get safety information regarding the Infanrix administration to a patient that should have received Boostrix but received Infanrix which led wrong vaccine administered The received Infanrix in non-recommended age which led inappropriate age at vaccine administration The Vaccine Administration Facility is the same as Primary Reporter. The reporter consented to follow up.